Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SpyGlass prepares for End of Phase II meeting with the FDA to advance its Drug Delivery Platform into Phase III pivotal studiesInnovative platform has the potential to enable all cataract surgeons to...
-
Mean intraocular pressure (IOP) was reduced by 43.7% from baseline at month 18All patients remained off topical IOP-lowering medications and achieved >20% IOP reductionAll eyes achieved Visual...
-
Share Mean intraocular pressure (IOP) reduction from washed-out baseline was 44.6% at Month 12; all patients had IOP reduction >20% and IOP ≤ 18 mmHg. 100% of patients remained off topical...
-
Margot Goodkin, M.D., Ph.D., appointed Chief Medical OfficerBilal Khan, MBA, CEO of New World Medical, appointed to the SpyGlass Board of Directors ALISO VIEJO, Calif., Dec. 05, 2023 (GLOBE...
-
Dublin, Nov. 24, 2023 (GLOBE NEWSWIRE) -- The "Ocular Hypertension - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.This "Ocular Hypertension - Pipeline...
-
ALISO VIEJO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today the initiation of a Phase I/II clinical trial...
-
ALISO VIEJO, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ophthalmic therapeutics company, released 6-month data from a First-in-Human glaucoma treatment trial showing...
-
Dublin, July 15, 2021 (GLOBE NEWSWIRE) -- The "Antiglaucoma Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering. The...
-
Dublin, Dec. 24, 2020 (GLOBE NEWSWIRE) -- The "Ocular Drug Delivery: Market Overview, Delivery Technologies and Partnering Opportunities, 2nd edition" report has been added to...